Induction of virus-specific cytotoxic T lymphocytes by in vivo electric administration of peptides

Vaccine

Volumn 19, Issue 15-16, 2001, Pages 2190-2196

  Uno Furuta, Satori ^a   Tamaki, Shigenori ^a   Takebe, Yutaka ^b   Takamura, Shiki ^a   Kamei, Akira ^a   Kim, Gisen ^a   Kuromatsu, Isao ^a   Kaito, Masahiko ^a   Adachi, Yukihiko ^a   Yasutomi, Yasuhiro ^a  

^a MIE UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

CTL; Immunostimulatory sequence (ISS); Peptide vaccine

Indexed keywords

B7 ANTIGEN; COMPLEMENTARY DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PROTEIN NS5; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; ELECTROPORATION; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD80; ANTIGENS, VIRAL; BASE SEQUENCE; ELECTROPORATION; HIV ANTIGENS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 0035961453     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00336-4     Document Type: Article

References (56)

1. Differences in antigen presentation to MHC class I and II-restricted influenza virus-specific cytolytic T lymphocyte clones
2. The immunological basis of vaccine development
3. Introduction of soluble protein into the class I pathway of the antigen presentation
4. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes
5. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
6. Peptide-induced antiviral protection by cytotoxic T cells
7. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide
8. Soluble proteins delivered to dendricted cells via pH-sensitive liposomes induce primary CTL responses in vitro
9. + cytotoxic T lymphocytes
10. Liposomes as carriers of peptide antigens: Induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides
11. Antibody and cytotoxic T lymphocytes responses to a single liposome-associated peptide antigen
12. + T cells with a predominant Vβ usage during the primary immune response to HIV
13. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
14. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
15. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
16. B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C
17. Vaccines to prevent viral hepatitis
18. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C
19. Induction of cytotoxic T cells a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein
20. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes
21. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses
22. The role of the B7-1a molecule, an alternatively spliced form of murine B7-1(CD80), on T cell activation
23. A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-α promoter elicits HCV-specific cytotoxic T lymphocytes (CTL)
24. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus
25. The influence of DNA sequence on the immunostumulatory properties of plasmid DNA vectors
26. CD28-mediated signalling co-stimulates murine T cells and prevents induction of energy in T-cell clones
27. Binding of the B cell activation antigen B7 to CD28 co-stimulates T cell proliferation and interleukin 2 mRNA accumulation
28. B70 antigen is a second ligand for CTLA-4 and CD28
29. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
30. Genetically modified tumor vaccines - Where we are today
31. CD4-independent in vivo priming of murine CTL by optimal MHC class-I restricted peptides derived from intracellular pathogens
32. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp120
33. + cytotoxic T lymphocytes in rhesus monkey
34. Immunization of mice immunized with lipopeptides bypasses the prerequisite for adjuvant: Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein
35. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
36. Liposome mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen
37. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy
38. Direct gene transfer into rat liver cells by in vivo electroporation
39. High-efficiency gene transfer into skeletal muscle mediated by electric pulses
40. Determination of optimal parameters for in vivo gene transfer by electroporation, using a rapid in vivo test for cell permiabilization
41. The B7 and CD28 receptor families
42. CD80(B7) and CD86(B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL
43. The T cell antigen, CD28, mediates adhesion with B cells by interacting with activation antigen, B7/BB-1
44. Gene-modified tumor cells as cellular vaccine
45. A mechanism for selective recruitment of CD8 T cells into B7-1 transfected Plasmacytoma
46. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1(CD80) and intercellular adhesive molecule 1(ICAM-1;CD54) transfection and recombinant interleukin 12
47. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes
48. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecule and cytokines
49. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity
50. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation
51. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
52. Induction of NK activity in murine and human cells by CpG motif in oligodeoxynucleotides and bacterial DNA
53. Bacterial DNA induced murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α
54. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-γ
55. CpG motif in bacterial DNA trigger direct B-cell activation
56. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-γ-dependent mechanisms